Product Description
Etomidate is an ultrashort-acting, non-barbiturate hypnotic intravenous anesthetic agent. It is administered only by intravenous route. Etomidate has a very favorable hemodynamic profile on induction, with a minimal amount of blood pressure depression, making it an ideal choice for shock trauma, hypovolemic patients, or patients with significant cardiovascular disease. Etomidate has been approved for use during induction of general anesthesia and rapid sequence intubation, as well as other indications where short-term anesthesia is warranted. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK535364/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Ecuador | Estonia | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Nhwa
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Anesthesia Related
Phase 2: Other
Phase 1: Bradycardia|Hypotension|Tachycardia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ET-26-HCl-202 | P2 |
Not yet recruiting |
Other |
2025-03-01 |
|
| ET-26-HCl-301 | P3 |
Recruiting |
Anesthesia Related |
2024-04-30 |
|
| HSK3486 SAD_04 | P1 |
Not yet recruiting |
Tachycardia|Anesthesia Related|Hypotension|Bradycardia |
2017-01-31 |